Last reviewed · How we verify
Nucleotidic or Nucleosidic Treatment
Nucleotidic or nucleosidic compounds inhibit viral reverse transcriptase and/or other viral enzymes to suppress replication of retroviruses or other nucleic acid-dependent pathogens.
Nucleotidic or nucleosidic compounds inhibit viral reverse transcriptase and/or other viral enzymes to suppress replication of retroviruses or other nucleic acid-dependent pathogens. Used for HIV infection (as part of combination antiretroviral therapy), Hepatitis B virus infection.
At a glance
| Generic name | Nucleotidic or Nucleosidic Treatment |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) |
| Target | Viral reverse transcriptase; viral polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease; Virology |
| Phase | Phase 3 |
Mechanism of action
This class of antivirals works by mimicking natural nucleotides or nucleosides and becoming incorporated into viral nucleic acid synthesis, causing chain termination or preventing proper viral enzyme function. These agents are commonly used against HIV and hepatitis B virus, targeting the viral reverse transcriptase or polymerase enzymes essential for viral replication.
Approved indications
- HIV infection (as part of combination antiretroviral therapy)
- Hepatitis B virus infection
Common side effects
- Mitochondrial toxicity / lactic acidosis
- Peripheral neuropathy
- Pancreatitis
- Lipodystrophy
- Gastrointestinal disturbance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: